Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy [Et randomiseret, dobbeltblindt, placebokontrolleret, verdensomspaendende, dosisbestemmende klinisk multicenterforsog i fase II med parallelle grupper med en bevis-for-effekt ledende kohorte, der vurderer sikkerhed, tolerance og effekt af MK-8457 + MTX til patienter med aktiv kronisk leddegigt pa trods af behandling med methotrexate].

Next Previous
Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy [Et randomiseret, dobbeltblindt, placebokontrolleret, verdensomspaendende, dosisbestemmende klinisk multicenterforsog i fase II med parallelle grupper med en bevis-for-effekt ledende kohorte, der vurderer sikkerhed, tolerance og effekt af MK-8457 + MTX til patienter med aktiv kronisk leddegigt pa trods af behandling med methotrexate].

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 8457 (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms AM2
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 16 Aug 2016 This trial was completed in Germany (End Date:2 Sep 2013).
  • 26 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
  • 06 Dec 2012 Planned End Date changed from 1 Nov 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top